# Fabrication of PLA-PEG Nanoparticles as Delivery Systems for Improved Stability and Controlled Release of Catechin

Authors: Neha Atulkumar Singh; Abul Kalam Azad Mandal; Zaved Ahmed Khan
Journal: Journal of Nanomaterials
 (2017)

---

## Abstract

The purpose of this study was to develop an oral delivery system for the controlled release of catechin and evaluate the antioxidant potential and stability of catechin loaded PLA/PEG nanoparticles (CATNP). Nanoparticles were synthesized using a double emulsion solvent evaporation method. The fabricated nanoparticles were relatively small with a hydrodynamic diameter of 300 nm and an encapsulation efficiency of 95%. SEM image analysis showed uniform sized and spherically shaped nanoparticles.In vitro release profiles indicated a slow and sustained release of catechin from the nanoparticle. Stability of the nanoparticle in simulated gastric and intestinal fluids is maintained due to the PEG coating on the nanoparticles, which effectively protected catechin against gastrointestinal enzyme activity. Enhanced inhibition action of free radicals and metal chelation potential was noted when catechin was encapsulated in these polymeric nanoparticles. The reports obtained from this study would provide an opportunity for designing an oral delivery system aimed at inhibiting oxidative stress in the human body.


---

## Body

## 1. Introduction

Oxidative degradation is one of the main processes involved in deterioration of foods, which results in reduced nutritive value and product shelf life [1]. This degradation can be triggered by free radicals. Reactive oxygen species including superoxide (O2-), hydrogen peroxide (H2O2), and the hydroxyl radical (OH) aggravate oxidative stress by generating new free radicals by converting elements they react with, setting up an autocatalytic chain reaction, which causes cell wall damage through lipid peroxidation. Further activation of these injury mechanisms leads to the development of clinical diseases including heart diseases, diabetes, liver injury, aging, and cancer [2, 3].Transition metals like iron, copper, or cobalt further accelerate this oxidative degradation, as they are ever-present as impurities in food products and the human system. Deposition of these metals damages various organs and disrupts their functioning [4]. Therefore, the perfect balance of free radicals and transition metals is very important for prevention of damage caused by oxidative stress. Nonetheless, some synthetic antioxidants and metal chelators are being used to delay the oxidation process in both food products and the human system. However, they are extremely costly and are associated with various side effects. There is, therefore, a need to develop natural compounds that are capable of preventing oxidative damage with minimum cost and side effects [2, 4].Extensive investigations on catechin and its derivatives have shown that they possess many beneficial properties including radical scavenging, metal chelation, and anticarcinogenic and anti-inflammatory activity. They have also shown generating a significant effect on cell viability and signaling pathways, which makes them a potential therapeutic agent for treatment of cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases in humans [5–7]. However, the use of these flavonoids is limited due to their poor stability and bioavailability. Factors like pH, temperature, oxygen, light, and gastrointestinal enzymes limit their beneficial properties [8]. Presently, the use of nanotechnology has been particularly useful in the delivery of similar bioactive compounds. Bioactive compound loaded nanoparticle-based approaches have shown great potential in protecting and controlling drug release, along with enhanced absorption and bioavailability [3].Therefore, the aim of the present study was to encapsulate catechin into polymer nanoparticle made of polylactic acid (PLA) and polyethylene glycol (PEG) copolymer and to characterize their stability, physiochemical, antioxidant, and metal chelation properties. The important aspects of this study included the determination of the encapsulation efficiency, in vitro release profiles, and stability studies in simulated gastric and intestinal fluids. The determination of the antioxidant and metal chelation potential of encapsulated catechin over free radicals and transition metals would further our understanding of how they would act in a human system or food products.This knowledge would consequently help facilitate the designing of an effective delivery system for bioactive compounds with the potential to improve human health and improve shelf life of food products. The protection and sustained release offered by this delivery system could make it suitable for use in pharmaceutical applications and for the development of functional foods. Here, the enhancement of encapsulated catechin’s antioxidant and metal chelation potential over free catechin would bring novelty to this study.


## 2. Materials and Methods

### 2.1. Materials

(+) Catechin (>97%), poly (D,L-lactic acid) (PLA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), pancreatin 3x, pepsin 1 : 1000, 3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine-p,p′-disulfonic acid monosodium salt hydrate (Ferrozine), pyrogallol (for synthesis), 2-thiobarbituric acid, 2,2-diphenyl-1-picrylhydrazyl (DPPH), and amyloid beta protein fragments 1–42 were purchased from Sigma Chemical Co. Dichloromethane (DCM) and absolute ethanol (Analytical Grade) were obtained from HiMedia Laboratories, India.


### 2.2. Preparation of Polymeric Nanoparticles

Double emulsion solvent evaporation method was employed with minor modifications for the synthesis of PLA/PEG nanoparticles [9]. Briefly, PLA and PEG were dissolved in DCM at the ratio of 75 : 25 and six different concentrations of catechin (1, 2, 5, 10, 12, and 15 mg/ml) were prepared in 0.1% PVA solution. Both solutions were mixed and sonicated for 30 s. About 0.7% of PVA solution was added to this mixture and sonicated for 1 min to form a water-oil-water emulsion. After evaporation of the organic solvent at room temperature, nanoparticles were recovered by centrifugation at 12,000g for 20 min at 4°C. The nanoparticles were washed twice with water to remove any remaining surfactants.


### 2.3. Characterization

HR-SEM (FEI Quanta FEG 200, High-Resolution Scanning Electron Microscope) was used to study the surface morphology of the nanoparticles (10 mg/ml). Hydrodynamic diameter and the zeta potential of CATNP (10 mg/ml) were determined using dynamic light scattering (Zetasizer with Ver. 6.12 software) [10]. To better understand the structure of free catechin (10 mg/ml), CATNP (10 mg/ml), and unloaded nanoparticles, Fourier transform infrared spectra (FT-IR) (FT-IR spectroscopy, Siemens 578564) and X-ray diffraction (XRD) patterns (X-ray diffraction instrument, D8 Advance, BRUKER, Germany) were recorded.


#### 2.3.1. Determination of Catechin Encapsulation Efficiency

Vanillin assay was used to determine the catechin encapsulation efficiency of six concentrations of CATNP, namely, 1, 2, 5, 10, 12, and 15 mg/ml. The measurements were taken at 500 nm with a UV-VIS spectrophotometer [11, 12]. (1)EE%=AmountofcatechinentrappedTotalamountofcatechin·100.All measurements were performed in triplicate.


#### 2.3.2.In Vitro Catechin Release from Nanoparticles

Dialysis bag diffusion technique with minor modifications was employed forin vitro catechin release studies [13]. The study was performed for six concentrations of CATNP, namely, 1, 2, 5, 10, 12, and 15 mg/ml. Briefly, the catechin was loaded in the dialysis bag and immersed in phosphate buffer solution (PBS) of pH 7.4. This system was stirred at 200 rpm at room temperature and samples were collected at specific time intervals. The study was carried out for over 40 h and samples were analyzed with a UV-VIS spectrophotometer.


#### 2.3.3. Mathematical Modeling of Release Kinetics

The release kinetics of CATNP (10 mg/ml) was studied to determine the mechanism of catechin release. Thein vitro release data for CATNP (10 mg/ml) under physiological conditions was fitted into various mathematical models including, zero-order, first-order, Higuchi, Hixson-Crowell, and Korsmeyer-Peppas models [14] (Table 1). To determine the best fit for each model value of the correlation coefficient (R2) was used as an indicator. Based on the release exponent (n) value, the release mechanism of the catechin was determined [15] (Table 2).Table 1
Equations and parameters of mathematical models.
Model
Equation
Parameter definition
Zero order
C
=
k
o
t
C: concentration of drug
k
o: zero-order constant
t: time
First order
log
⁡
C
o
-
log
⁡
C
t
=
k
1
t
2.303
C
o: initial concentration
C
t: concentration at time t
k
1: first-order constant
t: time
Higuchi model
Q
=
k
H
t
1
/
2
Q: amount of drug released in time t
k
H: Higuchi constant
t: time
Hixson-Crowell model
Q
o
1
/
3
-
Q
t
1
/
3
=
k
H
C
t
Q
o: initial amount of drug
Q
t: remaining amount of drug at time t
k
H
C: Hixson-Crowell constant
t: time
Korsmeyer-Peppas model
M
t
-
M
α
=
k
t
n
M
t
-
M
α: fraction of drug released at time t
k: Korsmeyer-Peppas constant
t: time
n: release exponentTable 2
Interpretation of diffusion release mechanisms.
Release exponent (n)
Drug transport mechanism
n
<
0.5
Fickian diffusion
0.45
<
n
<
0.89
Non-Fickian transport
0.89
Case II transport
0.89
<
n
Super case II transport


#### 2.3.4. Catechin Stability

Simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) were used to analyze the stability of CATNP (10 mg/ml). SGF and SIF were prepared with the addition of enzymes, pepsin and pancreatin, in SGF and SIF, respectively [16]. The tubes were incubated in an orbital shaker at 37°C with 130 rotations per minute (rpm). They were incubated for specific time intervals such as 5 min, 10 min, 15 min, 30 min, 1 h, 2 h, 3 h, and 6 h. After the specific time interval the samples were removed and the suspension was centrifuged at 8000 rpm for 10 min. The supernatant was collected and analyzed. The absorbance of samples collected at specific time intervals was analyzed using a UV-VIS spectrophotometer.


### 2.4. Antioxidant Assays

Antioxidant assays were carried out with 2 different groups, namely, free catechin (10 mg/ml) and CATNP (10 mg/ml).


#### 2.4.1. Superoxide Anion Scavenging

The free radical scavenging activity of the samples was measuredin vitro by superoxide anion scavenging assay [17]. Briefly, samples were dissolved in 75 mM Tris-HCl of pH 8.2 and incubated at 4°C for 1 h. Then 30 mM EDTA and 2 mM pyrogallol were added and the absorbance was taken at 470 nm using a UV-VIS spectrophotometer.(2)X=Absorbanceof0min-1min,Y=Absorbanceof2min2,Z=Absorbanceof3min3,B=X+Y+Z3,C1%ofantioxidation=BAAbsorbanceofcontrol·100,Inhibition%=C50·Totalvolumeofsolution0.5·10.5.


#### 2.4.2. Lipid Peroxidation

The free radical scavenging activity of the samples was also measuredin vitro by lipid peroxidation assay [18, 19]. Briefly, the samples were dissolved in 0.1 M Tris-HCl buffer of pH 7.4 and incubated at 37°C for 2 h with constant shaking. About 10% w/v TCA was added and the mixture was centrifuged at 5000 rpm for 10 min. An equal amount of 0.67% w/v TBA was added to the supernatant and incubated for 1 h in boiling water (100°C). The mixture was allowed to cool down and diluted in double distilled water, which was followed by centrifugation at 5000 rpm for 10 min. The absorbance of the upper organic layer was measured at 532 nm using a UV-VIS spectrophotometer.(3)Inhibition%=Absorbance0.015·1·10.2.


#### 2.4.3. DPPH Assay

The free radical scavenging activity of the samples was also measuredin vitroby DPPH assay [20]. Briefly, sample concentrations ranging between 10 and 500 μg/ml were prepared using appropriate solvents. About 0.1 M DPPH was prepared and added to the samples, which were then incubated in dark at room temperature for 30 min. The absorbance was measured at 517 nm using a UV-VIS spectrophotometer.(4)Scavengingactivity%=Absorbancecontrol-sampleAbsorbanceofcontrol·100.


### 2.5. Metal Chelating Activity Assay

The chelating activity of Fe2+ was measured by previously established protocols [2, 21]. Briefly, samples were dissolved in deionized water to which 2 mM FeCl2 was added. This mixture was allowed to stand for 30 s. To this 5 mM Ferrozine was added and incubated at room temperature for 10 min. The absorbance was measured at 562 nm using a UV-VIS spectrophotometer.(5)Chelationrate%=Absorbancecontrol-sampleAbsorbanceofcontrol·100.


## 2.1. Materials

(+) Catechin (>97%), poly (D,L-lactic acid) (PLA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), pancreatin 3x, pepsin 1 : 1000, 3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine-p,p′-disulfonic acid monosodium salt hydrate (Ferrozine), pyrogallol (for synthesis), 2-thiobarbituric acid, 2,2-diphenyl-1-picrylhydrazyl (DPPH), and amyloid beta protein fragments 1–42 were purchased from Sigma Chemical Co. Dichloromethane (DCM) and absolute ethanol (Analytical Grade) were obtained from HiMedia Laboratories, India.


## 2.2. Preparation of Polymeric Nanoparticles

Double emulsion solvent evaporation method was employed with minor modifications for the synthesis of PLA/PEG nanoparticles [9]. Briefly, PLA and PEG were dissolved in DCM at the ratio of 75 : 25 and six different concentrations of catechin (1, 2, 5, 10, 12, and 15 mg/ml) were prepared in 0.1% PVA solution. Both solutions were mixed and sonicated for 30 s. About 0.7% of PVA solution was added to this mixture and sonicated for 1 min to form a water-oil-water emulsion. After evaporation of the organic solvent at room temperature, nanoparticles were recovered by centrifugation at 12,000g for 20 min at 4°C. The nanoparticles were washed twice with water to remove any remaining surfactants.


## 2.3. Characterization

HR-SEM (FEI Quanta FEG 200, High-Resolution Scanning Electron Microscope) was used to study the surface morphology of the nanoparticles (10 mg/ml). Hydrodynamic diameter and the zeta potential of CATNP (10 mg/ml) were determined using dynamic light scattering (Zetasizer with Ver. 6.12 software) [10]. To better understand the structure of free catechin (10 mg/ml), CATNP (10 mg/ml), and unloaded nanoparticles, Fourier transform infrared spectra (FT-IR) (FT-IR spectroscopy, Siemens 578564) and X-ray diffraction (XRD) patterns (X-ray diffraction instrument, D8 Advance, BRUKER, Germany) were recorded.


### 2.3.1. Determination of Catechin Encapsulation Efficiency

Vanillin assay was used to determine the catechin encapsulation efficiency of six concentrations of CATNP, namely, 1, 2, 5, 10, 12, and 15 mg/ml. The measurements were taken at 500 nm with a UV-VIS spectrophotometer [11, 12]. (1)EE%=AmountofcatechinentrappedTotalamountofcatechin·100.All measurements were performed in triplicate.


### 2.3.2.In Vitro Catechin Release from Nanoparticles

Dialysis bag diffusion technique with minor modifications was employed forin vitro catechin release studies [13]. The study was performed for six concentrations of CATNP, namely, 1, 2, 5, 10, 12, and 15 mg/ml. Briefly, the catechin was loaded in the dialysis bag and immersed in phosphate buffer solution (PBS) of pH 7.4. This system was stirred at 200 rpm at room temperature and samples were collected at specific time intervals. The study was carried out for over 40 h and samples were analyzed with a UV-VIS spectrophotometer.


### 2.3.3. Mathematical Modeling of Release Kinetics

The release kinetics of CATNP (10 mg/ml) was studied to determine the mechanism of catechin release. Thein vitro release data for CATNP (10 mg/ml) under physiological conditions was fitted into various mathematical models including, zero-order, first-order, Higuchi, Hixson-Crowell, and Korsmeyer-Peppas models [14] (Table 1). To determine the best fit for each model value of the correlation coefficient (R2) was used as an indicator. Based on the release exponent (n) value, the release mechanism of the catechin was determined [15] (Table 2).Table 1
Equations and parameters of mathematical models.
Model
Equation
Parameter definition
Zero order
C
=
k
o
t
C: concentration of drug
k
o: zero-order constant
t: time
First order
log
⁡
C
o
-
log
⁡
C
t
=
k
1
t
2.303
C
o: initial concentration
C
t: concentration at time t
k
1: first-order constant
t: time
Higuchi model
Q
=
k
H
t
1
/
2
Q: amount of drug released in time t
k
H: Higuchi constant
t: time
Hixson-Crowell model
Q
o
1
/
3
-
Q
t
1
/
3
=
k
H
C
t
Q
o: initial amount of drug
Q
t: remaining amount of drug at time t
k
H
C: Hixson-Crowell constant
t: time
Korsmeyer-Peppas model
M
t
-
M
α
=
k
t
n
M
t
-
M
α: fraction of drug released at time t
k: Korsmeyer-Peppas constant
t: time
n: release exponentTable 2
Interpretation of diffusion release mechanisms.
Release exponent (n)
Drug transport mechanism
n
<
0.5
Fickian diffusion
0.45
<
n
<
0.89
Non-Fickian transport
0.89
Case II transport
0.89
<
n
Super case II transport


### 2.3.4. Catechin Stability

Simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) were used to analyze the stability of CATNP (10 mg/ml). SGF and SIF were prepared with the addition of enzymes, pepsin and pancreatin, in SGF and SIF, respectively [16]. The tubes were incubated in an orbital shaker at 37°C with 130 rotations per minute (rpm). They were incubated for specific time intervals such as 5 min, 10 min, 15 min, 30 min, 1 h, 2 h, 3 h, and 6 h. After the specific time interval the samples were removed and the suspension was centrifuged at 8000 rpm for 10 min. The supernatant was collected and analyzed. The absorbance of samples collected at specific time intervals was analyzed using a UV-VIS spectrophotometer.


## 2.3.1. Determination of Catechin Encapsulation Efficiency

Vanillin assay was used to determine the catechin encapsulation efficiency of six concentrations of CATNP, namely, 1, 2, 5, 10, 12, and 15 mg/ml. The measurements were taken at 500 nm with a UV-VIS spectrophotometer [11, 12]. (1)EE%=AmountofcatechinentrappedTotalamountofcatechin·100.All measurements were performed in triplicate.


## 2.3.2.In Vitro Catechin Release from Nanoparticles

Dialysis bag diffusion technique with minor modifications was employed forin vitro catechin release studies [13]. The study was performed for six concentrations of CATNP, namely, 1, 2, 5, 10, 12, and 15 mg/ml. Briefly, the catechin was loaded in the dialysis bag and immersed in phosphate buffer solution (PBS) of pH 7.4. This system was stirred at 200 rpm at room temperature and samples were collected at specific time intervals. The study was carried out for over 40 h and samples were analyzed with a UV-VIS spectrophotometer.


## 2.3.3. Mathematical Modeling of Release Kinetics

The release kinetics of CATNP (10 mg/ml) was studied to determine the mechanism of catechin release. Thein vitro release data for CATNP (10 mg/ml) under physiological conditions was fitted into various mathematical models including, zero-order, first-order, Higuchi, Hixson-Crowell, and Korsmeyer-Peppas models [14] (Table 1). To determine the best fit for each model value of the correlation coefficient (R2) was used as an indicator. Based on the release exponent (n) value, the release mechanism of the catechin was determined [15] (Table 2).Table 1
Equations and parameters of mathematical models.
Model
Equation
Parameter definition
Zero order
C
=
k
o
t
C: concentration of drug
k
o: zero-order constant
t: time
First order
log
⁡
C
o
-
log
⁡
C
t
=
k
1
t
2.303
C
o: initial concentration
C
t: concentration at time t
k
1: first-order constant
t: time
Higuchi model
Q
=
k
H
t
1
/
2
Q: amount of drug released in time t
k
H: Higuchi constant
t: time
Hixson-Crowell model
Q
o
1
/
3
-
Q
t
1
/
3
=
k
H
C
t
Q
o: initial amount of drug
Q
t: remaining amount of drug at time t
k
H
C: Hixson-Crowell constant
t: time
Korsmeyer-Peppas model
M
t
-
M
α
=
k
t
n
M
t
-
M
α: fraction of drug released at time t
k: Korsmeyer-Peppas constant
t: time
n: release exponentTable 2
Interpretation of diffusion release mechanisms.
Release exponent (n)
Drug transport mechanism
n
<
0.5
Fickian diffusion
0.45
<
n
<
0.89
Non-Fickian transport
0.89
Case II transport
0.89
<
n
Super case II transport


## 2.3.4. Catechin Stability

Simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) were used to analyze the stability of CATNP (10 mg/ml). SGF and SIF were prepared with the addition of enzymes, pepsin and pancreatin, in SGF and SIF, respectively [16]. The tubes were incubated in an orbital shaker at 37°C with 130 rotations per minute (rpm). They were incubated for specific time intervals such as 5 min, 10 min, 15 min, 30 min, 1 h, 2 h, 3 h, and 6 h. After the specific time interval the samples were removed and the suspension was centrifuged at 8000 rpm for 10 min. The supernatant was collected and analyzed. The absorbance of samples collected at specific time intervals was analyzed using a UV-VIS spectrophotometer.


## 2.4. Antioxidant Assays

Antioxidant assays were carried out with 2 different groups, namely, free catechin (10 mg/ml) and CATNP (10 mg/ml).


### 2.4.1. Superoxide Anion Scavenging

The free radical scavenging activity of the samples was measuredin vitro by superoxide anion scavenging assay [17]. Briefly, samples were dissolved in 75 mM Tris-HCl of pH 8.2 and incubated at 4°C for 1 h. Then 30 mM EDTA and 2 mM pyrogallol were added and the absorbance was taken at 470 nm using a UV-VIS spectrophotometer.(2)X=Absorbanceof0min-1min,Y=Absorbanceof2min2,Z=Absorbanceof3min3,B=X+Y+Z3,C1%ofantioxidation=BAAbsorbanceofcontrol·100,Inhibition%=C50·Totalvolumeofsolution0.5·10.5.


### 2.4.2. Lipid Peroxidation

The free radical scavenging activity of the samples was also measuredin vitro by lipid peroxidation assay [18, 19]. Briefly, the samples were dissolved in 0.1 M Tris-HCl buffer of pH 7.4 and incubated at 37°C for 2 h with constant shaking. About 10% w/v TCA was added and the mixture was centrifuged at 5000 rpm for 10 min. An equal amount of 0.67% w/v TBA was added to the supernatant and incubated for 1 h in boiling water (100°C). The mixture was allowed to cool down and diluted in double distilled water, which was followed by centrifugation at 5000 rpm for 10 min. The absorbance of the upper organic layer was measured at 532 nm using a UV-VIS spectrophotometer.(3)Inhibition%=Absorbance0.015·1·10.2.


### 2.4.3. DPPH Assay

The free radical scavenging activity of the samples was also measuredin vitroby DPPH assay [20]. Briefly, sample concentrations ranging between 10 and 500 μg/ml were prepared using appropriate solvents. About 0.1 M DPPH was prepared and added to the samples, which were then incubated in dark at room temperature for 30 min. The absorbance was measured at 517 nm using a UV-VIS spectrophotometer.(4)Scavengingactivity%=Absorbancecontrol-sampleAbsorbanceofcontrol·100.


## 2.4.1. Superoxide Anion Scavenging

The free radical scavenging activity of the samples was measuredin vitro by superoxide anion scavenging assay [17]. Briefly, samples were dissolved in 75 mM Tris-HCl of pH 8.2 and incubated at 4°C for 1 h. Then 30 mM EDTA and 2 mM pyrogallol were added and the absorbance was taken at 470 nm using a UV-VIS spectrophotometer.(2)X=Absorbanceof0min-1min,Y=Absorbanceof2min2,Z=Absorbanceof3min3,B=X+Y+Z3,C1%ofantioxidation=BAAbsorbanceofcontrol·100,Inhibition%=C50·Totalvolumeofsolution0.5·10.5.


## 2.4.2. Lipid Peroxidation

The free radical scavenging activity of the samples was also measuredin vitro by lipid peroxidation assay [18, 19]. Briefly, the samples were dissolved in 0.1 M Tris-HCl buffer of pH 7.4 and incubated at 37°C for 2 h with constant shaking. About 10% w/v TCA was added and the mixture was centrifuged at 5000 rpm for 10 min. An equal amount of 0.67% w/v TBA was added to the supernatant and incubated for 1 h in boiling water (100°C). The mixture was allowed to cool down and diluted in double distilled water, which was followed by centrifugation at 5000 rpm for 10 min. The absorbance of the upper organic layer was measured at 532 nm using a UV-VIS spectrophotometer.(3)Inhibition%=Absorbance0.015·1·10.2.


## 2.4.3. DPPH Assay

The free radical scavenging activity of the samples was also measuredin vitroby DPPH assay [20]. Briefly, sample concentrations ranging between 10 and 500 μg/ml were prepared using appropriate solvents. About 0.1 M DPPH was prepared and added to the samples, which were then incubated in dark at room temperature for 30 min. The absorbance was measured at 517 nm using a UV-VIS spectrophotometer.(4)Scavengingactivity%=Absorbancecontrol-sampleAbsorbanceofcontrol·100.


## 2.5. Metal Chelating Activity Assay

The chelating activity of Fe2+ was measured by previously established protocols [2, 21]. Briefly, samples were dissolved in deionized water to which 2 mM FeCl2 was added. This mixture was allowed to stand for 30 s. To this 5 mM Ferrozine was added and incubated at room temperature for 10 min. The absorbance was measured at 562 nm using a UV-VIS spectrophotometer.(5)Chelationrate%=Absorbancecontrol-sampleAbsorbanceofcontrol·100.


## 3. Results

### 3.1. Physiochemical Properties of Nanoparticles

Characterization was carried out for CATNP of 10 mg/ml concentration.


#### 3.1.1. Morphological and Electrical Properties

The surface morphology of CATNP was analyzed using HR-SEM (Figure1). It confirmed the formation of nanoparticles with a uniform, spherical to slightly ellipsoid shape, with a smooth surface. The average particle sizes were 300 nm. The hydrodynamic diameter of CATNP (10 mg/ml) was 342.1 nm (Figure 2(a)), while the zeta potential was −22.1 mV (Figure 2(b)).Figure 1
Surface morphology of CATNP (10 mg/ml).Figure 2
(a) Particle size and (b) zeta potential of CATNP (10 mg/ml).
(a)
(b)


#### 3.1.2. Nanoparticle Matrix Properties

The XRD patterns were measured for free catechin (10 mg/ml), CATNP (10 mg/ml), and unloaded nanoparticles. The XRD patterns of CATNP were similar to the unloaded nanoparticles rather than the free form of catechin (Figure3(a)). FT-IR analysis was also carried out for the same. Here CATNP represented the characteristic peaks of the free catechin, C=C stretch in the aromatic ring (1600 and 1475 cm−1) and OH stretch (3600–3200 cm−1) and the unloaded nanoparticles, -CH3 stretching (2850–3000 cm−1), C=O stretch (1700–1800 cm−1), and the C-O stretching of the oxygen ring (1050–1250 cm−1) (Figures 3(b), 3(c), and 3(d)).Figure 3
(a) XRD spectra of(1) unloaded nanoparticle, (2) CATNP (10 mg/ml), and (3) free catechin (10 mg/ml). FT-IR spectra of (b) free catechin (10 mg/ml), (c) CATNP (10 mg/ml), and (d) unloaded nanoparticle.
(a)
(b)
(c)
(d)


#### 3.1.3. Encapsulation Properties

The encapsulation efficiency was measured and is presented in Table3. Maximum encapsulation efficiency was found to be 95.50% for 10 mg/ml concentration of CATNP. The other concentrations of CATNP had encapsulation efficiencies ranging from 81.50 to 94.00%.Table 3
Encapsulation efficiency of different concentration of CATNP.
Concentration (mg/ml)
C
A
T
N
P
a  (%)
1
81.50 ± 1.80
2
82.75 ± 1.29
5
91.50 ± 1.44
10
95.50 ± 1.44
12
94.00 ± 1.73
15
93.00 ± 1.73
C
A
T
N
P
a: catechin encapsulated polymeric nanoparticles.


#### 3.1.4. In Vitro Release Assay

The in vitro release profiles of all concentrations of CATNP are presented in Figure4(a). CATNP at high concentrations displayed a sudden burst in catechin release. In the case of 10 mg/ml concentration of CATNP this burst was noted at the 7th h with the release of 45.58% of catechin from the nanoparticle. After the initial burst, sustained release of the catechin from the CATNP was noted and about 75.62% of the total catechin was released in 40 h.Figure 4
In vitro release study (a) of all concentrations for CATNP under physiological conditions and (b) of 10 mg/ml concentration of CATNP in simulated gastric fluid and simulated intestinal fluid.
(a)
(b)


#### 3.1.5. Mathematical Modeling of Release Kinetics

In vitro release profiles were fitted into various mathematical models to determine the release kinetics (Table4) and release mechanism of catechin (Table 5). Based on the correlation coefficient (R2) and release kinetic constant values, CATNP (10 mg/ml) formulation showed good correlation with Hixson-Crowell kinetics. The value of the release exponent (n) showed that the release mechanism followed was Fickian diffusion.Table 4
Release kinetics of catechin from nanocatechin (10 mg/ml) formulation.
Kinetic model
Correlation coefficient (R2)
Kinetic constant(k)
Zero order
0.9649
k
o = 0.0225
First order
0.9637
k
1 = 0.0014
Higuchi model
0.9649
k
H = 1.1022
Hixson-Crowell model
0.9701
k
H
C = 0.0035Table 5
Release mechanism of catechin from nanocatechin (10 mg/ml) formulation.
Kinetic model
Release exponent (n)
Korsmeyer-Peppas model
n
=
0.0828
Fickian diffusion


#### 3.1.6. Catechin Stability in Simulated Gastric and Intestinal Fluids

SGF and SIF were used to evaluate the stability of CATNP (10 mg/ml) under physiological conditions. The percentage of catechin remaining at the end of 3 h in SGF was 73.33%, while at the end of 6 h in SIF it was 63.75% (Figure4(b)).


### 3.2. Antioxidant Capacity

Figures5(a), 5(b), and 5(c) display the free radical scavenging ability for free catechin (10 mg/ml) and CATNP (10 mg/ml) measured over 40 h. Highest scavenging activity was noted at the initial burst hour (i.e., 7th hour), where CATNP showed DPPH free radical scavenging ability of around 93% with superoxide anion scavenging and lipid peroxidation activity of around 12% and 57%, respectively. A 1.64-, 1.65-, and 1.57-fold increase in activity for DPPH, lipid peroxidation, and superoxide scavenging assays was seen in CATNP.Figure 5
Antioxidant and metal chelation assays of free catechin (10 mg/ml) and CATNP (10 mg/ml). (a) Superoxide scavenging activity, (b) lipid peroxidation, (c) DPPH activity, and (d) metal chelation potential.
(a)
(b)
(c)
(d)


### 3.3. Metal Chelating Activity Assay

Figure5(d) displays the metal chelation ability for free catechin and CATNP. This activity was measured over 40 h. Highest chelation activity of 83% was noted at the initial burst hour. A 1.51-fold boost in activity was noted in the metal chelation rate of CATNP.


## 3.1. Physiochemical Properties of Nanoparticles

Characterization was carried out for CATNP of 10 mg/ml concentration.


### 3.1.1. Morphological and Electrical Properties

The surface morphology of CATNP was analyzed using HR-SEM (Figure1). It confirmed the formation of nanoparticles with a uniform, spherical to slightly ellipsoid shape, with a smooth surface. The average particle sizes were 300 nm. The hydrodynamic diameter of CATNP (10 mg/ml) was 342.1 nm (Figure 2(a)), while the zeta potential was −22.1 mV (Figure 2(b)).Figure 1
Surface morphology of CATNP (10 mg/ml).Figure 2
(a) Particle size and (b) zeta potential of CATNP (10 mg/ml).
(a)
(b)


### 3.1.2. Nanoparticle Matrix Properties

The XRD patterns were measured for free catechin (10 mg/ml), CATNP (10 mg/ml), and unloaded nanoparticles. The XRD patterns of CATNP were similar to the unloaded nanoparticles rather than the free form of catechin (Figure3(a)). FT-IR analysis was also carried out for the same. Here CATNP represented the characteristic peaks of the free catechin, C=C stretch in the aromatic ring (1600 and 1475 cm−1) and OH stretch (3600–3200 cm−1) and the unloaded nanoparticles, -CH3 stretching (2850–3000 cm−1), C=O stretch (1700–1800 cm−1), and the C-O stretching of the oxygen ring (1050–1250 cm−1) (Figures 3(b), 3(c), and 3(d)).Figure 3
(a) XRD spectra of(1) unloaded nanoparticle, (2) CATNP (10 mg/ml), and (3) free catechin (10 mg/ml). FT-IR spectra of (b) free catechin (10 mg/ml), (c) CATNP (10 mg/ml), and (d) unloaded nanoparticle.
(a)
(b)
(c)
(d)


### 3.1.3. Encapsulation Properties

The encapsulation efficiency was measured and is presented in Table3. Maximum encapsulation efficiency was found to be 95.50% for 10 mg/ml concentration of CATNP. The other concentrations of CATNP had encapsulation efficiencies ranging from 81.50 to 94.00%.Table 3
Encapsulation efficiency of different concentration of CATNP.
Concentration (mg/ml)
C
A
T
N
P
a  (%)
1
81.50 ± 1.80
2
82.75 ± 1.29
5
91.50 ± 1.44
10
95.50 ± 1.44
12
94.00 ± 1.73
15
93.00 ± 1.73
C
A
T
N
P
a: catechin encapsulated polymeric nanoparticles.


### 3.1.4. In Vitro Release Assay

The in vitro release profiles of all concentrations of CATNP are presented in Figure4(a). CATNP at high concentrations displayed a sudden burst in catechin release. In the case of 10 mg/ml concentration of CATNP this burst was noted at the 7th h with the release of 45.58% of catechin from the nanoparticle. After the initial burst, sustained release of the catechin from the CATNP was noted and about 75.62% of the total catechin was released in 40 h.Figure 4
In vitro release study (a) of all concentrations for CATNP under physiological conditions and (b) of 10 mg/ml concentration of CATNP in simulated gastric fluid and simulated intestinal fluid.
(a)
(b)


### 3.1.5. Mathematical Modeling of Release Kinetics

In vitro release profiles were fitted into various mathematical models to determine the release kinetics (Table4) and release mechanism of catechin (Table 5). Based on the correlation coefficient (R2) and release kinetic constant values, CATNP (10 mg/ml) formulation showed good correlation with Hixson-Crowell kinetics. The value of the release exponent (n) showed that the release mechanism followed was Fickian diffusion.Table 4
Release kinetics of catechin from nanocatechin (10 mg/ml) formulation.
Kinetic model
Correlation coefficient (R2)
Kinetic constant(k)
Zero order
0.9649
k
o = 0.0225
First order
0.9637
k
1 = 0.0014
Higuchi model
0.9649
k
H = 1.1022
Hixson-Crowell model
0.9701
k
H
C = 0.0035Table 5
Release mechanism of catechin from nanocatechin (10 mg/ml) formulation.
Kinetic model
Release exponent (n)
Korsmeyer-Peppas model
n
=
0.0828
Fickian diffusion


### 3.1.6. Catechin Stability in Simulated Gastric and Intestinal Fluids

SGF and SIF were used to evaluate the stability of CATNP (10 mg/ml) under physiological conditions. The percentage of catechin remaining at the end of 3 h in SGF was 73.33%, while at the end of 6 h in SIF it was 63.75% (Figure4(b)).


## 3.1.1. Morphological and Electrical Properties

The surface morphology of CATNP was analyzed using HR-SEM (Figure1). It confirmed the formation of nanoparticles with a uniform, spherical to slightly ellipsoid shape, with a smooth surface. The average particle sizes were 300 nm. The hydrodynamic diameter of CATNP (10 mg/ml) was 342.1 nm (Figure 2(a)), while the zeta potential was −22.1 mV (Figure 2(b)).Figure 1
Surface morphology of CATNP (10 mg/ml).Figure 2
(a) Particle size and (b) zeta potential of CATNP (10 mg/ml).
(a)
(b)


## 3.1.2. Nanoparticle Matrix Properties

The XRD patterns were measured for free catechin (10 mg/ml), CATNP (10 mg/ml), and unloaded nanoparticles. The XRD patterns of CATNP were similar to the unloaded nanoparticles rather than the free form of catechin (Figure3(a)). FT-IR analysis was also carried out for the same. Here CATNP represented the characteristic peaks of the free catechin, C=C stretch in the aromatic ring (1600 and 1475 cm−1) and OH stretch (3600–3200 cm−1) and the unloaded nanoparticles, -CH3 stretching (2850–3000 cm−1), C=O stretch (1700–1800 cm−1), and the C-O stretching of the oxygen ring (1050–1250 cm−1) (Figures 3(b), 3(c), and 3(d)).Figure 3
(a) XRD spectra of(1) unloaded nanoparticle, (2) CATNP (10 mg/ml), and (3) free catechin (10 mg/ml). FT-IR spectra of (b) free catechin (10 mg/ml), (c) CATNP (10 mg/ml), and (d) unloaded nanoparticle.
(a)
(b)
(c)
(d)


## 3.1.3. Encapsulation Properties

The encapsulation efficiency was measured and is presented in Table3. Maximum encapsulation efficiency was found to be 95.50% for 10 mg/ml concentration of CATNP. The other concentrations of CATNP had encapsulation efficiencies ranging from 81.50 to 94.00%.Table 3
Encapsulation efficiency of different concentration of CATNP.
Concentration (mg/ml)
C
A
T
N
P
a  (%)
1
81.50 ± 1.80
2
82.75 ± 1.29
5
91.50 ± 1.44
10
95.50 ± 1.44
12
94.00 ± 1.73
15
93.00 ± 1.73
C
A
T
N
P
a: catechin encapsulated polymeric nanoparticles.


## 3.1.4. In Vitro Release Assay

The in vitro release profiles of all concentrations of CATNP are presented in Figure4(a). CATNP at high concentrations displayed a sudden burst in catechin release. In the case of 10 mg/ml concentration of CATNP this burst was noted at the 7th h with the release of 45.58% of catechin from the nanoparticle. After the initial burst, sustained release of the catechin from the CATNP was noted and about 75.62% of the total catechin was released in 40 h.Figure 4
In vitro release study (a) of all concentrations for CATNP under physiological conditions and (b) of 10 mg/ml concentration of CATNP in simulated gastric fluid and simulated intestinal fluid.
(a)
(b)


## 3.1.5. Mathematical Modeling of Release Kinetics

In vitro release profiles were fitted into various mathematical models to determine the release kinetics (Table4) and release mechanism of catechin (Table 5). Based on the correlation coefficient (R2) and release kinetic constant values, CATNP (10 mg/ml) formulation showed good correlation with Hixson-Crowell kinetics. The value of the release exponent (n) showed that the release mechanism followed was Fickian diffusion.Table 4
Release kinetics of catechin from nanocatechin (10 mg/ml) formulation.
Kinetic model
Correlation coefficient (R2)
Kinetic constant(k)
Zero order
0.9649
k
o = 0.0225
First order
0.9637
k
1 = 0.0014
Higuchi model
0.9649
k
H = 1.1022
Hixson-Crowell model
0.9701
k
H
C = 0.0035Table 5
Release mechanism of catechin from nanocatechin (10 mg/ml) formulation.
Kinetic model
Release exponent (n)
Korsmeyer-Peppas model
n
=
0.0828
Fickian diffusion


## 3.1.6. Catechin Stability in Simulated Gastric and Intestinal Fluids

SGF and SIF were used to evaluate the stability of CATNP (10 mg/ml) under physiological conditions. The percentage of catechin remaining at the end of 3 h in SGF was 73.33%, while at the end of 6 h in SIF it was 63.75% (Figure4(b)).


## 3.2. Antioxidant Capacity

Figures5(a), 5(b), and 5(c) display the free radical scavenging ability for free catechin (10 mg/ml) and CATNP (10 mg/ml) measured over 40 h. Highest scavenging activity was noted at the initial burst hour (i.e., 7th hour), where CATNP showed DPPH free radical scavenging ability of around 93% with superoxide anion scavenging and lipid peroxidation activity of around 12% and 57%, respectively. A 1.64-, 1.65-, and 1.57-fold increase in activity for DPPH, lipid peroxidation, and superoxide scavenging assays was seen in CATNP.Figure 5
Antioxidant and metal chelation assays of free catechin (10 mg/ml) and CATNP (10 mg/ml). (a) Superoxide scavenging activity, (b) lipid peroxidation, (c) DPPH activity, and (d) metal chelation potential.
(a)
(b)
(c)
(d)


## 3.3. Metal Chelating Activity Assay

Figure5(d) displays the metal chelation ability for free catechin and CATNP. This activity was measured over 40 h. Highest chelation activity of 83% was noted at the initial burst hour. A 1.51-fold boost in activity was noted in the metal chelation rate of CATNP.


## 4. Discussion

### 4.1. Synthesis of Catechin Loaded PLA/PEG Nanoparticles

Double solvent evaporation method was employed for the encapsulation of catechin into PLA/PEG nanoparticles. Sonication at low temperatures was carried out in order to synthesize emulsions with enhanced antioxidant and metal chelation potential [22]. Here, PVA was used as a surfactant to maintain the stability of the emulsion during solvent evaporation. This single volume shrinkage of the emulsion droplets led to the generation of nanoparticles [23, 24]. Additionally, these nanoparticles were coated with PEG to enhance the drug’s bioavailability and stability [25]. Our studies suggested that the PEG coating on the nanoparticles protected approximately 60% of catechin against gastrointestinal enzyme activity.


### 4.2. Characterization of Catechin Loaded PLA/PEG Nanoparticles

Physiochemical properties hold much importance in determining functional performance [26], toxicity, drug loading, targeting ability, biological activity, release, and stability [27]. CATNP synthesized in this study had particle sizes ranging from 200 nm to 400 nm. They also had strong electrostatic repulsion forces which prevented their aggregation as their zeta potentials were −22.1 mV [28].XRD and FT-IR spectra analysis attested to the successful encapsulation of catechin into PLA/PEG nanoparticles. Based on previous XRD studies we know that free catechin is crystalline in nature [29, 30] and unloaded nanoparticles are amorphous in nature [8]. The XRD spectra for CATNP had peaks that closely resembled those generated by the unloaded nanoparticles rather than its free form. Similarly the FT-IR spectra analysis showed characteristic peaks for free catechin, C=C stretch in the aromatic ring (1600 and 1475 cm−1) and OH stretch (3600–3200 cm−1) and unloaded nanoparticles, -CH3 stretching (2850–3000 cm−1), C=O stretch (1700–1800 cm−1), and the C-O stretching of the oxygen ring (1050–1250 cm−1) which were in support with the previous literature [31–33]. But the spectra analysis for CATNP showed characteristic peaks from both free catechin and unloaded nanoparticles with only a slight shift in space, thus attesting to the positive encapsulation of catechin into PLA/PEG nanoparticles. Furthermore, the encapsulation efficiency of catechin into PLA/PEG nanoparticles holds much importance and is mainly dependent on drug solubility, polymer composition, and functional groups [34, 35]. For CATNP the encapsulation efficiency was approximately 95%, which suggested that very little catechin was partitioned into the aqueous phase during nanoparticle synthesis.


### 4.3. Release Rate and Antioxidant Potential of Catechin Loaded PLA/PEG Nanoparticles

In vitro catechin release profiles were generated for different concentration of CATNP under physiological conditions. It was noted that catechin release from CATNP was faster for the first few hours followed by a slow and sustained release in the later hours. In support with previous studies, we observed an initial catechin burst at the 7th h, which was considered to be due to the diffusion of catechin molecules present on the nanoparticle surface. This was followed by a slow and sustained release that was attributed to the flow of the catechin molecules entrapped in the core of the nanoparticle [36]. Hence, a positive correlation was noted between catechin load and sustained release which signified the importance of drug load as a variable in release rate profiles [37]. Further analysis of the release kinetics and mechanism of release of catechin was carried out. The release kinetics CATNP (10 mg/ml) formulation was in correlation with the Hixson-Crowell model, which mainly applies to pharmaceutical dosage forms and followed Fickian release; that is, the release was through the mode of diffusion [14]. This supports the burst release hypothesis and attests to the fact that the drug burst was not due to nanoparticle degradation or erosion.Catechin release was also studied under SGF and SIF conditions to better understand the protective role of the PEG coating. Release rate profiles recorded protection of 60% catechin against the activity of gastrointestinal enzymes. Based on previous literature, we can assume that the addition of PEG to the nanoparticle shell prevented enzyme docking on polymer surface which in turn prevented drug and nanoparticle shell degradation [16]. The need of a protective coating of PEG is further attested by an earlier study on PLA nanoparticles without any protective coating, which showed strong drug degradation in simulated gastric and intestinal fluids. Here only 11% and 34% of PLA nanoparticles maintained their integrity in simulated gastric and intestinal fluids, respectively [38].Antioxidant and metal chelation potentials were studied for free catechin and CATNP in a time-dependent manner to determine their ability to prevent lipid, protein, and DNA oxidation through hydrogen donation [39]. It was noted that CATNP greatly enhanced the radical scavenging activity of free catechin 1.64-, 1.65-, and 1.57-fold for DPPH, lipid peroxidation, and superoxide scavenging assays. Likewise, a 1.51-fold boost was also noted in the metal chelation rate. This suggested that encapsulation of catechin into PLA/PEG nanoparticles greatly enhanced the stability and antioxidant and metal chelation potential of free catechin.


## 4.1. Synthesis of Catechin Loaded PLA/PEG Nanoparticles

Double solvent evaporation method was employed for the encapsulation of catechin into PLA/PEG nanoparticles. Sonication at low temperatures was carried out in order to synthesize emulsions with enhanced antioxidant and metal chelation potential [22]. Here, PVA was used as a surfactant to maintain the stability of the emulsion during solvent evaporation. This single volume shrinkage of the emulsion droplets led to the generation of nanoparticles [23, 24]. Additionally, these nanoparticles were coated with PEG to enhance the drug’s bioavailability and stability [25]. Our studies suggested that the PEG coating on the nanoparticles protected approximately 60% of catechin against gastrointestinal enzyme activity.


## 4.2. Characterization of Catechin Loaded PLA/PEG Nanoparticles

Physiochemical properties hold much importance in determining functional performance [26], toxicity, drug loading, targeting ability, biological activity, release, and stability [27]. CATNP synthesized in this study had particle sizes ranging from 200 nm to 400 nm. They also had strong electrostatic repulsion forces which prevented their aggregation as their zeta potentials were −22.1 mV [28].XRD and FT-IR spectra analysis attested to the successful encapsulation of catechin into PLA/PEG nanoparticles. Based on previous XRD studies we know that free catechin is crystalline in nature [29, 30] and unloaded nanoparticles are amorphous in nature [8]. The XRD spectra for CATNP had peaks that closely resembled those generated by the unloaded nanoparticles rather than its free form. Similarly the FT-IR spectra analysis showed characteristic peaks for free catechin, C=C stretch in the aromatic ring (1600 and 1475 cm−1) and OH stretch (3600–3200 cm−1) and unloaded nanoparticles, -CH3 stretching (2850–3000 cm−1), C=O stretch (1700–1800 cm−1), and the C-O stretching of the oxygen ring (1050–1250 cm−1) which were in support with the previous literature [31–33]. But the spectra analysis for CATNP showed characteristic peaks from both free catechin and unloaded nanoparticles with only a slight shift in space, thus attesting to the positive encapsulation of catechin into PLA/PEG nanoparticles. Furthermore, the encapsulation efficiency of catechin into PLA/PEG nanoparticles holds much importance and is mainly dependent on drug solubility, polymer composition, and functional groups [34, 35]. For CATNP the encapsulation efficiency was approximately 95%, which suggested that very little catechin was partitioned into the aqueous phase during nanoparticle synthesis.


## 4.3. Release Rate and Antioxidant Potential of Catechin Loaded PLA/PEG Nanoparticles

In vitro catechin release profiles were generated for different concentration of CATNP under physiological conditions. It was noted that catechin release from CATNP was faster for the first few hours followed by a slow and sustained release in the later hours. In support with previous studies, we observed an initial catechin burst at the 7th h, which was considered to be due to the diffusion of catechin molecules present on the nanoparticle surface. This was followed by a slow and sustained release that was attributed to the flow of the catechin molecules entrapped in the core of the nanoparticle [36]. Hence, a positive correlation was noted between catechin load and sustained release which signified the importance of drug load as a variable in release rate profiles [37]. Further analysis of the release kinetics and mechanism of release of catechin was carried out. The release kinetics CATNP (10 mg/ml) formulation was in correlation with the Hixson-Crowell model, which mainly applies to pharmaceutical dosage forms and followed Fickian release; that is, the release was through the mode of diffusion [14]. This supports the burst release hypothesis and attests to the fact that the drug burst was not due to nanoparticle degradation or erosion.Catechin release was also studied under SGF and SIF conditions to better understand the protective role of the PEG coating. Release rate profiles recorded protection of 60% catechin against the activity of gastrointestinal enzymes. Based on previous literature, we can assume that the addition of PEG to the nanoparticle shell prevented enzyme docking on polymer surface which in turn prevented drug and nanoparticle shell degradation [16]. The need of a protective coating of PEG is further attested by an earlier study on PLA nanoparticles without any protective coating, which showed strong drug degradation in simulated gastric and intestinal fluids. Here only 11% and 34% of PLA nanoparticles maintained their integrity in simulated gastric and intestinal fluids, respectively [38].Antioxidant and metal chelation potentials were studied for free catechin and CATNP in a time-dependent manner to determine their ability to prevent lipid, protein, and DNA oxidation through hydrogen donation [39]. It was noted that CATNP greatly enhanced the radical scavenging activity of free catechin 1.64-, 1.65-, and 1.57-fold for DPPH, lipid peroxidation, and superoxide scavenging assays. Likewise, a 1.51-fold boost was also noted in the metal chelation rate. This suggested that encapsulation of catechin into PLA/PEG nanoparticles greatly enhanced the stability and antioxidant and metal chelation potential of free catechin.


## 5. Conclusion

Polymer nanoparticles were synthesized to encapsulate a bioactive flavonoid, catechin. Here catechin was encapsulated successfully in a noncrystalline state with an encapsulation efficiency of 96%. Release profiles of catechin from CATNP showed a slow and sustained release suggesting that PLA/PEG nanoparticles were suitable for catechin encapsulation and release in acidic environment, such as the gastric and intestinal systems. These reports can be useful in designing a delivery system for specific compounds in the stomach for treatment of local diseases. A significant increase in the antioxidant and metal chelation potentials of CATNP was also observed. These finding can be useful in designing a delivery system for delaying oxidative stress and improving shelf life of food products. However, further in vitro and in vivo studies are required to better understand the effects of CATNP. Nonetheless, this type of delivery system could be suitable for the encapsulation of bioactive compounds with beneficial properties for human health.



---

*Source: 6907149-2017-09-14.xml*